Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
We performed a systematic review and meta-analysis to assess the efficacy and tolerability
of degarelix for lower urinary tract symptom relief, prostate volume reduction and
quality of life improvement in men with prostate cancer (PCa).